Menzel Garry E

CIK 00015560646 companiesSAN DIEGO, CA

SEC Profile

Transactions

Companies

Filings

CIK

0001556064

Recent Transactions

50 trades

Award
Black Diamond Therapeutics, Inc.$BDTX
Stock Option (Right to Buy)
2025-06-12+30,550→ 30,550 total
Award
Stoke Therapeutics, Inc.$STOK
Director Stock Option (Right to Buy)
2025-06-03+29,747→ 29,747 total
Award
Adaptimmune Therapeutics PLC$ADAP
Option to purchase Ordinary Shares
2024-07-01+1,121,604→ 1,121,604 total
Award
Black Diamond Therapeutics, Inc.$BDTX
Stock Option (Right to Buy)
2024-06-06+30,550→ 30,550 total
Award
Stoke Therapeutics, Inc.$STOK
Director Stock Option (Right to Buy)
2024-06-05+7,639→ 7,639 total
Sale
Adaptimmune Therapeutics PLC$ADAP
American Depositary Shares representing Ordinary Shares
2023-07-10$0.91/sh−47,702→ 75,056 total
Award
Adaptimmune Therapeutics PLC$ADAP
Option to Purchase Ordinary Shares
2023-07-05+2,715,816→ 2,715,816 total
Award
Adaptimmune Therapeutics PLC$ADAP
Option to Purchase Ordinary Shares
2023-07-05+1,251,966→ 1,251,966 total
Award
Adaptimmune Therapeutics PLC$ADAP
Option to Purchase Ordinary Shares
2023-07-05+736,548→ 736,548 total
Award
Adaptimmune Therapeutics PLC$ADAP
Option to Purchase Ordinary Shares
2023-07-05+359,700→ 359,700 total
Award
Adaptimmune Therapeutics PLC$ADAP
Option to Purchase Ordinary Shares
2023-07-05+2,158,776→ 2,158,776 total
Award
Adaptimmune Therapeutics PLC$ADAP
Option to Purchase Ordinary Shares
2023-07-05+57,846→ 57,846 total
Award
Adaptimmune Therapeutics PLC$ADAP
Option to Purchase Ordinary Shares
2023-07-05+3,568,026→ 3,568,026 total
Award
Adaptimmune Therapeutics PLC$ADAP
Option to purchase Ordinary Shares
2023-07-03+981,463→ 981,463 total
Award
Stoke Therapeutics, Inc.$STOK
Director Stock Option (Right to Buy)
2023-06-13+19,441→ 19,441 total
Disposition to Issuer
TCR2 THERAPEUTICS INC.
Stock Option (Right to Buy)
2023-06-01−305,800→ 0 total
Disposition to Issuer
TCR2 THERAPEUTICS INC.
Restricted Stock Unit
2023-06-01−3,241→ 0 total
Disposition to Issuer
TCR2 THERAPEUTICS INC.
Restricted Stock Unit
2023-06-01−15,120→ 0 total
Disposition to Issuer
TCR2 THERAPEUTICS INC.
Restricted Stock Unit
2023-06-01−23,165→ 0 total
Disposition to Issuer
TCR2 THERAPEUTICS INC.
Common Stock
2023-06-01−132,729→ 0 total
Disposition to Issuer
TCR2 THERAPEUTICS INC.
Common Stock
2023-06-01−138,871→ 0 total
Award
Adaptimmune Therapeutics PLC$ADAP
American Depositary Shares representing Ordinary Shares
2023-06-01+209,931→ 209,931 total
Award
Adaptimmune Therapeutics PLC$ADAP
American Depositary Shares representing Ordinary Shares
2023-06-01+200,646→ 200,646 total
Disposition to Issuer
TCR2 THERAPEUTICS INC.
Stock Option (Right to Buy)
2023-06-01−433,037→ 0 total
Disposition to Issuer
TCR2 THERAPEUTICS INC.
Stock Option (Right to Buy)
2023-06-01−238,008→ 0 total
Award
Adaptimmune Therapeutics PLC$ADAP
American Depositary Shares representing Ordinary Shares
2023-06-01+200,647→ 200,647 total
Disposition to Issuer
TCR2 THERAPEUTICS INC.
Common Stock
2023-06-01−132,730→ 0 total
Disposition to Issuer
TCR2 THERAPEUTICS INC.
Restricted Stock Unit
2023-06-01−39,681→ 0 total
Disposition to Issuer
TCR2 THERAPEUTICS INC.
Stock Option (Right to Buy)
2023-06-01−138,031→ 0 total
Award
Black Diamond Therapeutics, Inc.$BDTX
Stock Option (Right to Buy)
2023-05-16+16,500→ 16,500 total
Award
TCR2 THERAPEUTICS INC.
Restricted Stock Unit (Right to Buy)
2022-12-15+39,681→ 39,681 total
Award
TCR2 THERAPEUTICS INC.
Stock Option (Right to Buy)
2022-12-15+238,008→ 238,008 total
Sale
TCR2 THERAPEUTICS INC.
Common Stock
2022-12-13$1.06/sh−11,000→ 138,871 total
Sale
TCR2 THERAPEUTICS INC.
Common Stock
2022-12-12$1.10/sh−10,613→ 149,871 total
Sale
TCR2 THERAPEUTICS INC.
Common Stock
2022-12-09$1.13/sh−10,325→ 160,484 total
Sale
TCR2 THERAPEUTICS INC.
Common Stock
2022-12-08$1.25/sh−9,314→ 170,809 total
Sale
TCR2 THERAPEUTICS INC.
Common Stock
2022-12-07$1.28/sh−9,111→ 180,123 total
Sale
TCR2 THERAPEUTICS INC.
Common Stock
2022-12-06$1.35/sh−14,886→ 189,234 total
Sale
TCR2 THERAPEUTICS INC.
Common Stock
2022-12-05$1.37/sh−8,530→ 204,120 total
Sale
TCR2 THERAPEUTICS INC.
Common Stock
2022-12-02$1.39/sh−8,408→ 212,650 total
Exercise/Conversion
TCR2 THERAPEUTICS INC.
Common Stock
2022-12-01+221,058→ 221,058 total
Exercise/Conversion
TCR2 THERAPEUTICS INC.
Restricted Stock Unit
2022-12-01+40,881→ 15,120 total
Exercise/Conversion
TCR2 THERAPEUTICS INC.
Restricted Stock Unit
2022-12-01+21,382→ 23,165 total
Exercise/Conversion
TCR2 THERAPEUTICS INC.
Restricted Stock Unit
2022-12-01+158,795→ 3,241 total
Award
TCR2 THERAPEUTICS INC.
Restricted Stock Unit (right to buy)
2022-11-17+159,956→ 159,956 total
Disposition to Issuer
TCR2 THERAPEUTICS INC.
Stock Option (right to buy)
2022-11-17−3,500→ 0 total
Award
TCR2 THERAPEUTICS INC.
Restricted Stock Unit (right to buy)
2022-11-17+1,167→ 1,167 total
Award
TCR2 THERAPEUTICS INC.
Restricted Stock Unit (right to buy)
2022-11-17+821→ 821 total
Award
TCR2 THERAPEUTICS INC.
Restricted Stock Unit (right to buy)
2022-11-17+54,834→ 54,834 total
Disposition to Issuer
TCR2 THERAPEUTICS INC.
Stock Option (right to buy)
2022-11-17−240,488→ 0 total

Companies

Recent Filings

Address

C/O REGULUS THERAPEUTICS INC. 3545 JOHN HOPKINS COURT, SUITE 210

SAN DIEGO, CA, 92121

View on SEC.gov